Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic exposure of novel oral nano-amorphous sirolimus to the currently used intravenously administered temsirolimus in healthy volunteers: A dose escalation study

Next Previous
Search
Trial Profile

Pharmacokinetic exposure of novel oral nano-amorphous sirolimus to the currently used intravenously administered temsirolimus in healthy volunteers: A dose escalation study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Temsirolimus (Primary)
  • Indications Coronary artery restenosis; Fibroma; Kasabach-Merritt syndrome; Lymphangioleiomyomatosis; Renal transplant rejection; Systemic lupus erythematosus
  • Focus Pharmacokinetics

Most Recent Events

  • 14 May 2019 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
  • 25 Jun 2018 New trial record
  • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top